Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Antibody-Drug Conjugates | Special Topics | Trends and Market Dynamics – Multi-indication | G7 | 2022

Login to access report north_east
Contact sales account_box

Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of antibody-drug conjugates continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates and analyzes the market trends and dynamics in a range of oncology indications.

QUESTIONS ANSWERED

  • What is the timeline and current landscape for approved antibody-drug conjugates? What are the trends in each key oncology indication?
  • How will emerging antibody-drug conjugates be positioned in the market? How will the indication-specific market trends and dynamics evolve?
  • What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, combination type, and geography? How will the market evolve over the 2021-2031 forecast period?

GEOGRAPHIES

United States, EU5, Japan.

EPIDEMIOLOGY

Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.

FORECAST

10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.

KEY DRUGS COVERED

Currently approved agents targeting HER2, TROP-2 and CD79b.

EMERGING THERAPIES

Phase III

PRODUCT DESCRIPTION

Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Migraine | Special Topics | Spotlight on New Treatments in Migraine (US) | 2021
Since 2018, seven novel drugs have entered the U.S. market for the acute or preventive treatment of migraine, and at least four more are on the short-term horizon. Understanding how prescribers…
north_east
Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
north_east
Report
Chimeric Antigen Receptor (CAR) T-Cell Therapy – Access & Reimbursement – Access & Reimbursement – Chimeric Antigen Receptor (CAR) T-Cell Therapy (US)
Ever since Novartis’s Kymriah became the first chimeric antigen receptor (CAR) T-cell therapy approved by the FDA for a cancer indication (acute lymphoblastic leukemia) in 2017, this class of…
north_east
Report
Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…
north_east
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Malignant Melanoma (US)
Biomarker-driven prescribing is vital in the treatment of key oncology indications, particularly non-small-cell lung cancer (NSCLC), colorectal cancer, and malignant melanoma. Treatment of these…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east